Arylamine N-acetyltransferases: from structure to function
- PMID: 18642144
- DOI: 10.1080/03602530802186603
Arylamine N-acetyltransferases: from structure to function
Abstract
Arylamine N-acetyltransferases (NATs) are cytosolic conjugating enzymes which transfer an acetyl group from acetylCoenzyme A to a xenobiotic acceptor substrate. The enzyme has an active site cysteine as part of a catalytic triad with histidine and aspartate. NATs have had an important role in pharmacogenetics. Polymorphism in acetylation (and inactivation) of the anti-tubercular agent isoniazid resides in human NAT2, one of two polymorphic human NATs. In humans there is also a third pseudogene and in rodents there are three isozymes. Comparison of human and rodent NAT enzymes and their genes is aiding our understanding of the roles of the individual isoenzymes. This may have clinical importance since human NAT1 is overexpressed in a sub-population of breast cancers and control of expression of the NAT genes is ripe for investigation. The mammalian NAT enzymes are involved in metabolism of drugs and carcinogens but there is growing evidence, including from transgenic mice, that human NAT1 has an endogenous role in folate degradation. Structural studies and intracellular tracking of polymorphic NAT variants, is contributing to appreciation of how individual mutations result in loss of NAT activity. Genome analyses have identified NAT homologues in bacteria including Mycobacterium tuberculosis, in which the NAT enzyme metabolises inactivation of isoniazid. More intriguingly, deletion of the nat gene in mycobacteria, leads to deficits in cell wall synthesis. Structural comparisons of NATs from prokaryotes and eukaryotes, particularly in relation to CoA binding, provide a platform for understanding how the unique NAT protein fold may lend itself to a wide range of functions.
Similar articles
-
Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.Toxicology. 2008 Dec 30;254(3):170-83. doi: 10.1016/j.tox.2008.08.022. Epub 2008 Sep 12. Toxicology. 2008. PMID: 18852012 Review.
-
Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.Biochem Soc Trans. 2003 Jun;31(Pt 3):615-9. doi: 10.1042/bst0310615. Biochem Soc Trans. 2003. PMID: 12773167 Review.
-
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.Br J Pharmacol. 2014 Jun;171(11):2705-25. doi: 10.1111/bph.12598. Br J Pharmacol. 2014. PMID: 24467436 Free PMC article. Review.
-
The pharmacogenetics of NAT: structural aspects.Pharmacogenomics. 2002 Jan;3(1):19-30. doi: 10.1517/14622416.3.1.19. Pharmacogenomics. 2002. PMID: 11966400 Review.
-
Arylamine N-acetyltransferases - of mice, men and microorganisms.Trends Pharmacol Sci. 2001 Mar;22(3):140-6. doi: 10.1016/s0165-6147(00)01639-4. Trends Pharmacol Sci. 2001. PMID: 11239577 Review.
Cited by
-
Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer.BMC Cancer. 2014 Dec 20;14:990. doi: 10.1186/1471-2407-14-990. BMC Cancer. 2014. PMID: 25528056 Free PMC article.
-
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.PLoS One. 2015 Jul 1;10(7):e0129711. doi: 10.1371/journal.pone.0129711. eCollection 2015. PLoS One. 2015. PMID: 26132585 Free PMC article.
-
A pilot study of the modulation of sirtuins on arylamine N-acetyltransferase 1 and 2 enzymatic activity.Acta Pharm Sin B. 2018 Mar;8(2):188-199. doi: 10.1016/j.apsb.2017.11.008. Epub 2017 Dec 30. Acta Pharm Sin B. 2018. PMID: 29719779 Free PMC article.
-
N-acetyltransferase 2 activity and folate levels.Life Sci. 2010 Jan 16;86(3-4):103-6. doi: 10.1016/j.lfs.2009.11.008. Epub 2009 Nov 20. Life Sci. 2010. PMID: 19932120 Free PMC article.
-
Recent advancements in enzyme engineering via site-specific incorporation of unnatural amino acids.World J Microbiol Biotechnol. 2021 Nov 6;37(12):213. doi: 10.1007/s11274-021-03177-1. World J Microbiol Biotechnol. 2021. PMID: 34741210 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources